Vanda Pharmaceuticals Announces US Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
- Consumers can now order NEREUS instantly at nereus.us
WASHINGTON, May 1, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) at present introduced that NEREUS (tradipitant) is now commercially obtainable throughout the United States for the prevention of vomiting induced by movement in adults, marking the first new prescription drugs authorised for this situation in greater than 40 years. An revolutionary direct-to-consumer order platform is now obtainable by means of nereus.us.
Motion illness impacts an estimated 65 to 78 million Americans—roughly 25 to 30 p.c of adults—throughout on a regular basis journey by automobile, aircraft, or boat. For many years, sufferers have had no significant new remedy choices. That adjustments at present with NEREUS, an oral neurokinin-1 (NK-1) receptor antagonist that provides a contemporary, focused strategy to an issue that has lengthy lacked innovation.
“Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel,” stated Mihael H. Polymeropoulos, MD, President, CEO and Chairman of Vanda. “NEREUS is a selective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1) receptors that can block the vomiting center of the brain. We are excited to make this innovative therapy available through both traditional pharmacy channels and our new direct-to-consumer platform at nereus.usgiving travelers, families, and anyone affected by motion sickness convenient access to a long-awaited solution.”
NEREUS is accessible now by prescription instantly by means of nereus.us and retail pharmacies nationwide. Through the devoted direct-to-consumer portal at nereus.ussufferers with a legitimate prescription can entry NEREUS at a cash-pay value of simply $85 per dose, a significant low cost from the normal record value of $255 per dose.
Throughout historical past, movement illness has repeatedly undermined navy effectiveness and human exploration. During Napoleon’s 1798 Egyptian marketing campaign, troopers in his newly shaped camel corps—referred to as the “ships of the desert”—suffered weakening nausea and vomiting from the animals’ swaying gait, rendering many unfit for battle and even affecting Napoleon himself. On D-Day in 1944, hundreds of Allied paratroopers endured violent air illness throughout turbulent flights over the English Channel earlier than they even reached Normandy. In the house age, practically 70 p.c of astronauts have confronted house adaptation syndrome, a type of movement illness that has challenged each main house program since the Nineteen Sixties. For greater than 4 many years, no new pharmacologic remedy emerged to handle this historic affliction—till at present.
Motion illness might happen when the mind receives conflicting indicators from the eyes, internal ear, and physique whereas on movement. This sensory mismatch is believed to set off the launch of substance P, which prompts NK-1 receptors in the central nervous system and in the end results in nausea and vomiting. NEREUS works by blocking these receptors, interrupting the vomiting pathway.
The US Food and Drug Administration authorised NEREUS on December 30, 2025, following two pivotal Phase 3 scientific trials—Motion Syros and Motion Serifos—performed beneath real-world situations on the open sea. Both research demonstrated that NEREUS considerably prevented vomiting in comparison with placebo, confirming the drug’s effectiveness in present sea journey situations. It is the first new prescription possibility for folks with a historical past of movement illness in over 40 years. It employs a novel mechanism as a selective, high-affinity antagonist of human substance P/NK-1 receptors. It provides easy dosing with only one or two capsules a day taken roughly an hour earlier than journey.
The business availability of NEREUS marks a historic milestone in addressing this extremely prevalent physiological response to movement that has plagued people for millennia.
Visit nereus.us to entry the direct-to-consumer portal and study extra about NEREUS.
About Vanda Pharmaceuticals
Vanda is a number one world biopharmaceutical firm centered on the growth and commercialization of revolutionary therapies to handle excessive unmet medical wants and enhance the lives of sufferers. For extra on Vanda Pharmaceuticals Inc., please go to www.vandapharma.com and comply with us on X @vandapharma.
About NEREUS
Indication and Important Safety Information for NEREUS (tradipitant) capsules.
INDICATION
NEREUS (NEER-ee-us) [tradipitant] is a prescription treatment used for the prevention of vomiting induced by movement in adults.
IMPORTANT SAFETY INFORMATION
NEREUS might impair skills required for driving a motorcar or working heavy equipment. Combining NEREUS with sedatives or drugs that improve NEREUS ranges might improve this impact. If use collectively can’t be prevented, your physician might warn in opposition to driving or working heavy equipment.
The most typical unwanted effects related with NEREUS embody drowsiness, headache, and fatigue.
Tell your healthcare supplier about all of the medicines you are taking. Strong CYP3A4 inhibitors might improve NEREUS ranges and the danger of unwanted effects.
Tell your healthcare supplier about all of your well being situations, together with if in case you have liver or kidney issues, or if you’re pregnant, planning to grow to be pregnant, or breastfeeding. There are restricted knowledge on NEREUS use in pregnant ladies.
Monitor breastfed infants for drowsiness.
The security and effectiveness of NEREUS for the prevention of vomiting induced by movement in kids haven’t been established.
NEREUS just isn’t beneficial in sufferers with liver issues or extreme kidney issues.
Consumer Important Safety Information
You are inspired to report unwanted effects of pharmaceuticals to the FDA. To report unwanted effects, contact Vanda Pharmaceuticals Inc. at 1-844-GO-VANDA (1-844-468-2632) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For extra info, ask your healthcare supplier or name 1-844-468-2632.
This info doesn’t take the place of speaking with your healthcare supplier for medical recommendation about your situation or remedy.
Download the full US Prescribing Information at nereus.us.
NEREUS (tradipitant) is a neurokinin-1 receptor antagonist FDA authorised for the acute prevention of vomiting induced by movement in adults, and is presently in scientific growth for a spread of different indications, together with gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. For full Prescribing Information and different sources, please go to nereus.us.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press launch, together with, however not restricted to statements concerning the prevalence of movement illness; the potential causes of movement illness and the methods in which it could be triggered; and Vanda’s additional scientific growth plans for NEREUS for numerous indications, together with gastroparesis and vomiting induced by GLP-1 receptor agonists are “forward-looking statements” beneath the securities legal guidelines. All statements aside from statements of historic reality are statements that could possibly be deemed forward-looking statements. Forward-looking statements are based mostly upon present expectations and assumptions that contain dangers, adjustments in circumstances and uncertainties. Important elements that would trigger precise outcomes to vary materially from these mirrored in Vanda’s forward-looking statements embody, amongst others, the accuracy of the estimates of the prevalence of movement illness; Vanda’s assumptions concerning the causes of movement illness and the methods in which it could be triggered; and Vanda’s means to proceed to advance tradipitant in gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. Therefore, no assurance might be provided that the outcomes or developments anticipated by Vanda will likely be realized, or even when considerably realized, that they’ll have the anticipated penalties to, or results on, Vanda. Forward-looking statements in this press launch needs to be evaluated collectively with the numerous dangers and uncertainties that have an effect on Vanda’s enterprise and market, significantly these recognized in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most up-to-date Annual Report on Form 10-Okay, as up to date by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-Okay and different filings with the US Securities and Exchange Commission, which can be found at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any individual appearing on her behalf are expressly certified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions buyers to not rely too closely on the forward-looking statements Vanda makes or which might be made on its behalf. The info in this press launch is offered solely as of the date of this press launch, and Vanda undertakes no obligation, and particularly declines any obligation, to replace or publicly revise any forward-looking statements, whether or not consequently of new info, future occasions or in any other case, besides as required by regulation.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]
SOURCE Vanda Pharmaceuticals Inc.
